Pembrolizumab (KEYTRUDA) Drug Profile and Competitive Landscape 2026
Pembrolizumab (KEYTRUDA): Drug Profile & Landscape
Pembrolizumab is a humanized monoclonal antibody targeting the PD-1 receptor, blocking PD-L1 and PD-L2 to restore anti-tumor immune activity. First approved September 2014 by Merck & Co., it now spans 332 indications.
Pembrolizumab (KEYTRUDA) Overview
Pembrolizumab (brand name KEYTRUDA) is a humanized monoclonal antibody originated by Merck & Co., Inc., first approved on September 4, 2014. It holds approved global development status and has accumulated 332 indications in the dataset, making it one of the most broadly indicated oncology agents on record.
Pembrolizumab targets the PD-1 (Programmed Cell Death Protein 1) receptor expressed on T lymphocytes and immune effector cells. By occupying PD-1, it sterically blocks PD-L1 and PD-L2 binding, releasing the immunological brake on tumor-infiltrating T cells, restoring cytotoxic activity against tumor-associated antigens, and enhancing cytokine-mediated immune responses within the tumor microenvironment.
Explicitly retrieved indications include platinum-resistant primary peritoneal carcinoma, platinum-resistant epithelial ovarian carcinoma, and mismatch repair-deficient colonic cancer. Deal evidence further implicates pembrolizumab across melanoma, NSCLC, head and neck cancer, renal cell carcinoma, HER2-positive solid tumors, biliary cancer, gastric/GEJ cancer, and dMMR/MSI-High metastatic colorectal cancer.
Active commercialization is managed by three Merck Sharp & Dohme entities: Merck Sharp & Dohme Corp. (US), Merck Sharp & Dohme (Ireland) Ltd., and Merck Sharp & Dohme BV (Netherlands), reflecting a coordinated global distribution infrastructure. Twenty active clinical collaboration deals (2022–2024) position KEYTRUDA as a universal combination backbone partner across the oncology pipeline.
Pembrolizumab Competitors on the PD-1 Axis
The dataset retrieves 5 competitors on the same PD-1/immuno-oncology axis. Nivolumab is the only other approved monospecific PD-1 antibody in this set, while RC-148, Lorigerlimab (bispecifics), and Budigalimab (pipeline monospecific) represent earlier-stage competition.
Competitor Drugs by Approval Status and Type
Pembrolizumab and nivolumab are the only approved agents; three pipeline drugs — two bispecifics and one monospecific — remain without reported approval dates.
↗ Click bars to explorePembrolizumab Clinical Collaboration Deal Activity by Year (2022–2024)
Deal volume peaked in 2023 with 11 active clinical collaborations, with continued momentum of 6 deals in 2024 and 3 deals initiating in 2022.
↗ Click bars to explorePembrolizumab Indications and Disease Areas
The dataset records 332 total indications for pembrolizumab, including explicitly retrieved tumor-specific entries and a broad range of oncology areas inferred from active clinical collaboration deals spanning 2022 to 2024.
Platinum-Resistant Ovarian & Peritoneal Carcinoma
Pembrolizumab is recorded with indications in both platinum-resistant epithelial ovarian carcinoma and platinum-resistant primary peritoneal carcinoma in the dataset. These represent biomarker-defined patient populations within gynecologic oncology where PD-1 blockade is being evaluated. The dataset does not specify the approval stage for these entries.
OncologydMMR Mismatch Repair-Deficient Colonic Cancer
Mismatch repair-deficient (dMMR) colonic cancer is explicitly listed as a retrieved indication for pembrolizumab in the dataset. Clinical collaboration evidence further supports evaluation in dMMR/MSI-High metastatic colorectal cancer, with Nouscom’s NOUS-209 neoantigen vaccine being evaluated in combination with KEYTRUDA in this patient population (January 2023 deal). The dataset does not specify the exact approval stage for this entry.
OncologyNon-Small Cell Lung Cancer (NSCLC)
NSCLC, including patients with low or absent PD-L1 expression, is identified as an active indication area through the 2023 Wellmarker Bio collaboration evaluating WM-A1-3389 in combination with KEYTRUDA. This deal explicitly targets a patient population with low/absent PD-L1, confirming Merck’s strategy to expand pembrolizumab utility beyond biomarker-selected populations. The dataset also identifies NSCLC through the broader indication framework.
OncologyMelanoma & Head and Neck Cancer
Melanoma is inferred as an active pembrolizumab indication area from the 2023 Microbiotica Phase 1b collaboration evaluating microbiome modulator MB097 in combination with KEYTRUDA. Head and neck cancer, including HPV16-positive disease, is supported by two separate collaborations: the 2024 Exelixis deal (zanzalintinib) and the 2022 Nykode Therapeutics collaboration evaluating therapeutic vaccine VB10.16 in HPV16-positive patients.
OncologyOrganizations in the Pembrolizumab Ecosystem
Merck & Co., Inc. originated pembrolizumab, with active commercialization managed by three MSD entities across the US, Ireland, and the Netherlands. The deal ecosystem spans 20 active clinical collaborations with biotech partners globally, while the patent assignee landscape includes Merck Sharp & Dohme Corp. (3 patents), Novartis AG (2 patents), and two active third-party holders — Halozyme Inc and Famewave Ltd.
Top Patent Assignees by Filing Count — Pembrolizumab Landscape
↗ Click bars to exploreMerck & Co., Inc.
Merck & Co., Inc. is the originator of pembrolizumab (KEYTRUDA), which received its first approval on September 4, 2014. Active commercialization is managed by three affiliated entities: Merck Sharp & Dohme Corp. (US), Merck Sharp & Dohme (Ireland) Ltd., and Merck Sharp & Dohme BV (Netherlands). Merck holds 3 retrieved patents (all inactive) covering PD-1 bioassays, gene signature biomarkers, and anti-PD-L1 detection, and has executed 20 active clinical collaboration deals from October 2022 through October 2024.
United StatesHalozyme Inc
Halozyme Inc holds one of only two currently active patents in the retrieved pembrolizumab landscape: US20170218069A1, covering a hyaluronidase plus immune checkpoint inhibitor combination delivery strategy. This active patent represents enforceable third-party IP directly relevant to pembrolizumab combination development programs. Halozyme’s combination delivery technology sits at the intersection of drug formulation and checkpoint immunotherapy, a space Merck’s pipeline actively engages through 20 clinical collaborations.
United StatesStrategic Outlook for Pembrolizumab in 2026
Pembrolizumab’s deal pattern and IP landscape reveal a drug operating as a global combination backbone, with Merck’s strategy concentrated on label expansion through partner-driven clinical collaborations rather than standalone monospecific competition.
Combination Strategy as Primary Growth Engine
All 20 retrieved deals are active clinical trial collaborations positioning KEYTRUDA as the combination backbone partner, spanning modalities from tyrosine kinase inhibitors (zanzalintinib, RXC004) to T cell therapies (TAC01-HER2), therapeutic vaccines (NOUS-209, VB10.16), microbiome modulators (MB097), and novel checkpoint inhibitors (GV20-0251 targeting IGSF8, BI-1910 targeting TNFR2). BD teams evaluating any oncology asset should assess KEYTRUDA combination potential early, as Merck’s high deal volume suggests structured and repeatable co-development frameworks are in place. A subset of deals explicitly targets PD-L1-low or absent patient populations, confirming expansion beyond current biomarker-selected groups.
Third-Party IP in Combination Space Warrants Monitoring
Two active patents in the retrieved landscape are held by non-Merck entities: Halozyme’s hyaluronidase plus checkpoint inhibitor combination delivery patent (US20170218069A1) and Famewave’s anti-CEACAM1 plus anti-PD combination therapy patent (US20170166637A1). These represent enforceable third-party rights directly relevant to pembrolizumab combination development. IP strategists should assess freedom-to-operate implications for any new combination therapy program involving KEYTRUDA alongside these mechanism classes.
Pembrolizumab (KEYTRUDA) Drug Profile Landscape Patent Position Summary
| Total Patents | 20 |
| Active Patents | 2 |
| Key Assignee | Merck Sharp & Dohme Corp |
| Earliest Filing | 2012 |
| Primary Themes | Biomarkers, combination therapy, diagnostics, target modulation |
Pembrolizumab vs. Nivolumab: PD-1 Inhibitor Comparison
Click any row to explore further in PatSnap Eureka.
| Dimension | Pembrolizumab (KEYTRUDA) | Nivolumab |
|---|---|---|
| Drug Type | Monoclonal antibody (humanized) | Monoclonal antibody |
| Primary Target | PD-1 (Programmed Cell Death Protein 1) | PD-1 (Programmed Cell Death Protein 1) |
| Mechanism of Action | PD-1 inhibitor — blocks PD-L1 and PD-L2 binding to restore T cell activity | PD-1 inhibitor — same axis |
| Global Status | Approved | Approved |
| First Approved | September 4, 2014 | July 4, 2014 |
| Total Indications | 332 (dataset) | Not specified in dataset |
| Originator | Merck & Co., Inc. | Bristol Myers Squibb |
| Active Organizations | Merck Sharp & Dohme Corp.; MSD Ireland Ltd.; MSD BV | Not specified in dataset |
Frequently Asked Questions: Pembrolizumab (KEYTRUDA)
Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 (Programmed Cell Death Protein 1) receptor expressed on T lymphocytes and immune effector cells. It works as a PD-1 inhibitor by occupying the PD-1 receptor and sterically blocking the binding of its ligands PD-L1 and PD-L2, which tumors exploit to evade immune surveillance. This blockade restores cytotoxic T cell activity directed against tumor-associated antigens and enhances cytokine-mediated immune responses within the tumor microenvironment.
The dataset records 332 total indications for pembrolizumab. Explicitly retrieved indications include platinum-resistant primary peritoneal carcinoma, platinum-resistant epithelial ovarian carcinoma, and mismatch repair-deficient (dMMR) colonic cancer. Deal evidence further supports active evaluation in NSCLC, melanoma, head and neck cancer (including HPV16-positive), renal cell carcinoma, biliary cancer, gastric/GEJ cancer, dMMR/MSI-High metastatic colorectal cancer, and HER2-positive solid tumors. The full approved vs. investigational distribution of all 332 indications is not confirmed in the available dataset.
Pembrolizumab was originated by Merck & Co., Inc. Active commercial organizations listed in the dataset are Merck Sharp & Dohme Corp. (United States), Merck Sharp & Dohme (Ireland) Ltd. (Ireland), and Merck Sharp & Dohme BV (Netherlands), collectively managing a coordinated global distribution infrastructure under the Merck parent.
The dataset retrieves 5 competitors on the same PD-1/immuno-oncology axis: Nivolumab (monoclonal antibody, approved July 2014 by Bristol Myers Squibb), Budigalimab (pipeline monoclonal antibody, no reported approval date), RC-148 (bispecific antibody, pipeline), and Lorigerlimab (bispecific antibody, pipeline). Nivolumab is the only head-to-head approved comparator in the dataset. The competitive dataset is noted as limited to 5 entries and the actual PD-1 inhibitor landscape is broader.
The dataset retrieves 20 deals, all classified as active clinical trial collaborations or clinical development collaborations spanning October 2022 through October 2024, with all financial values undisclosed. Notable collaborations include Exelixis (zanzalintinib, head and neck cancer/RCC, 2024), Dragonfly Therapeutics (DF9001 EGFR TriNKET, solid tumors, 2024), Microbiotica (MB097 microbiome modulator, melanoma, 2023), Nouscom (NOUS-209 neoantigen vaccine, dMMR/MSI-H CRC, 2023), Triumvira (TAC01-HER2 T cell therapy, HER2+ solid tumors, 2023), and Nykode Therapeutics (VB10.16 therapeutic vaccine, HPV16+ head and neck cancer, 2022).
A total of 20 patents were retrieved in the dataset. Only 2 are currently active: Halozyme Inc’s hyaluronidase plus checkpoint inhibitor combination delivery patent (US20170218069A1) and Famewave Ltd’s anti-CEACAM1 plus anti-PD combination therapy patent (US20170166637A1). The remaining 18 are either inactive or at expired PCT stages. Merck Sharp & Dohme Corp holds 3 retrieved patents (all inactive), covering PD-1 bioassays, gene signature biomarkers, and anti-PD-L1 detection. The dataset does not include pembrolizumab’s foundational composition-of-matter patents.
Data and insights on this page are based on a limited patent, clinical, and biopharma intelligence dataset and are for reference only.